{
      "ptx_code": "PTX191",
      "chem_name": "Ciprofloxacin",
      "casrn": "85721-33-1",
      "dtxsid": "DTXSID8022824",
      "smiles": "OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O",
      "inchikey": "MYSWGUAQZAJSOK-UHFFFAOYSA-N",
      "label": "PTX191 | Ciprofloxacin",
      "drugbank_id": "DB00537",
      "use_class": "Pharmaceutical",
      "tox_class": "Ototoxicity; Genotoxicity; Nephrotoxicity; Hepatotoxicity",
      "chem_name_user": "Ciprofloxacin",
      "mw_g_mol": "331.35",
      "solubility_h2o_mol_liter": "6.58e-03",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "9.24e-12",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "9.42",
      "source_kaw": "LSER eq 1 exp. Descriptors",
      "pka_acid": "5.86",
      "pka_base": "",
      "source_pka": "ACD/GALAS",
      "log_kow_liter_liter": "0.28",
      "source_kow": "",
      "log_dlipw_ph74_liter_liter": "-2.24",
      "source_dlipw": "Kow QSAR (\u2206mw = 1)",
      "freely_dissolved_fraction": "0.94",
      "density_kg_liter": "1.37",
      "source_density": "COMPTOX",
      "average_mass": "331.35",
      "boiling_point": "",
      "source_boiling_point": "",
      "melting_point": "255.0 \u00b0C",
      "source_melting_point": "LKT Labs (Chemical company)",
      "vapor_pressure": "",
      "source_vapor_pressure": "",
      "baseline_drerio": "1621810.10",
      "baseline_dmagna": "218776.16",
      "baseline_celegans": "457088.19",
      "baseline_xlaevis": "31067.05",
      "baseline_dmelanogaster": "2022087.76",
      "baseline_cells": "0.28",
      "baseline_cells_generic_micromole_liter_free_ec10": "0.26",
      "moa_drugbank": "Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin's targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]",
      "protein_binding": "20-40%.[Label,A178876]",
      "moa_t3db": "The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.",
      "aop": [],
      "targets": [
            "DNA topoisomerase 2-alpha",
            "Potassium voltage-gated channel subfamily H member 2",
            "Serum albumin"
      ]
}